Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis
Open accessThe DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We have developed a new antihyperglycemic agent (teglicar) through the selective and reversible inhibition of the liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1). RESEARCH DESIGN AND METHODS: Glucose production was investigated in isolated hepatocytes and during pancreatic clamps in healthy rats. Chronic treatments on C57BL/6J, db/db, high-fat fed mice, and rats were performed to understand glucose metabolism and insulin sensitivity. RESULTS: In isolated hepatocytes, teglicar concentration dependently reduced ketone bodies and glucose production up to 72 and 50%, respectively. In rats, teglicar reduced the endogenous glucose production (−62%) without affecting peripheral glucose utilization. Heart 2-[3H]deoxyglucose uptake in mice was also not affected, confirming in vivo the drug selectivity toward L-CPT1. Chronic treatment in db/db mice (50 mg/kg/bid; 45 days) reduced postabsorptive glycemia (−38%), water consumption (−31%), and fructosamine (−30%). Such antidiabetic activity was associated with an improved insulin sensitivity assessed by the insulin tolerance test. A significant 50% increase in hepatic triglyceride content (HTGC) was found, although plasma alanineaminotransferase was not altered. In addition, long-term teglicar administration to high-fat fed C57BL/6J mice normalized glycemia (−19%) and insulinemia (−53%). Long-term teglicar administration (30 days, 80 mg/kg) in healthy overnight-fasted rats slightly reduced basal glycemia (−20%, ns), reduced basal insulin levels by 60%, doubled triglycerides, and increased free-fatty acids (+53%). HTGC was markedly increased, but liver and peripheral insulin sensitivity assessed by hyperinsulinemiceuglycemic clamp were not affected. CONCLUSIONS: Teglicar, in vitro and in animal models, reduces gluconeogenesis and improves glucose homeostasis, refreshing the interest in selective and reversible L-CPT1 inhibition as a potential antihyperglycemic approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![FIG. 2. A: Pancreatic clamp procedure involves the infusion of 0.4 μCi/min [3-3H]glucose, 1.5 μg/kg/min somatostatin, and 0.7 mU/kg/min insulin. Control rats received saline throughout the experiment, whereas teglicar infusion was started at 120'. Rats receiving the drug also received glucose to prevent hypoglycemia. B: Representation of teglicar-induced drop in glycemia during pancreatic clamp. Euglycemia is restored by glucose coinfusion. C: Rates of glucose production before (EGP1) and during (EGP2) the infusion of teglicar (white bars) or saline (black bars) in postabsorptive SD rats. The box plots indicate the mean ± SE from five different pancreatic clamps/group. *P < 0.05 vs. saline.](https://figures.cochat.ai/paper-figures/8875472cd4674a46820fea716db102b5/selective-reversible-inhibition-of-liver-carnitine-palmitoyl-transferase-1-by-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Similar conclusions were reached by two meta-analyses that included these and other studies129,130.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [129]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093 · cited 1×
“In fact, an increase of peripheral GU would be indicative of an ongoing reversed Randle effect (28,29) through inhibition of MCPT1.”
BackgroundPathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085
The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis
McGarry, J. D., & Brown, N. F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00001.x · Cited by 1,616 · cited 1×
“CPT1 (12) is a ubiquitous enzyme that plays a pivotal role in mitochondrial fatty acid b-oxidation.”
BackgroundForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 1×
“The recent discovery (42) that metformin reduces hepatic gluconeogenesis independently of the LKB1/AMPK pathway, which, instead, blunts metformin efficacy, opens up the possibility of an advantageous association with L-CPT1 inhibitors.”
BackgroundReduced Food Intake and Body Weight in Mice Treated with Fatty Acid Synthase Inhibitors
Loftus, T. M., Jaworsky, D. E., Frehywot, G. L., Townsend, C. A., Ronnett, G. V., Lane, M. D., & Kuhajda, F. P. (2000) · Science · doi:10.1126/science.288.5475.2379 · Cited by 1,004
STANLEY, J. C. (1981) · British Journal of Anaesthesia · doi:10.1093/bja/53.2.123 · Cited by 731
Obici, S., Feng, Z., Arduini, A., Conti, R., & Rossetti, L. (2003) · Nature Medicine · doi:10.1038/nm873 · Cited by 548
Self-citationDose-response curves for in vivo insulin sensitivity in individual tissues in rats
Kraegen, E. W., James, D. E., Jenkins, A. B., & Chisholm, D. J. (1985) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1985.248.3.e353 · Cited by 408
[19] Assay of peroxisomal β-oxidation of fatty acids
Lazarow, P. B. (1981) · Methods in Enzymology · doi:10.1016/s0076-6879(81)72021-4 · Cited by 367
Dobbins, R. L., Szczepaniak, L. S., Bentley, B., Esser, V., Myhill, J., & McGarry, J. D. (2001) · Diabetes · doi:10.2337/diabetes.50.1.123 · Cited by 315 · cited 2×
“Etomoxir, a CPT1 inhibitor with hypoglycemic activity in diabetic patients, was abandoned because of its inability to distinguish between the liver (L-CPT1) and the muscle (M-CPT1) isoform of CPT1, causing undesirable cardiac effects (16) and, possibly, muscle insulin resistance (17).”
Background
Research works printed but not linked: 1
- Walter, 1976, Pyruvate carboxylase: intracellular localization and regulation, 239
Cited by
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
The interaction of hepatic lipid and glucose metabolism in liver diseases
Bechmann, L. P., Hannivoort, R. A., Gerken, G., Hotamisligil, G. S., Trauner, M., & Canbay, A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.025 · Cited by 994
CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential
Schlaepfer, I. R., & Joshi, M. (2020) · Endocrinology · doi:10.1210/endocr/bqz046 · Cited by 732
Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer
Qu, Q., Zeng, F., Liu, X., Wang, Q. J., & Deng, F. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.132 · Cited by 545
CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis
Wang, Y.-N., Zeng, Z.-L., Lu, J., Wang, Y., Liu, Z.-X., He, M.-M., Zhao, Q., Wang, Z.-X., Li, T., Lu, Y.-X., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0384-z · Cited by 380
Metadata
- Authors
- Conti, R., Mannucci, E., Pessotto, P., Tassoni, E., Carminati, P., Giannessi, F., & Arduini, A.
- Affiliations
- Sigma Tau (Italy) (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Paolo Carminati, sigma-tau s.p.a, Rome, Italy
- Corresponding author
- Conti, Roberto
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-01-21
- Volume
- 60
- Issue
- 2
- Pages
- 644-651
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3028366
- OpenAlex
- W1986038576
- Cited by
- 98
- References
- 46
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 10 · 2021: 6 · 2020: 4 · 2019: 9 · 2018: 7 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 3 · 2013: 4 · 2012: 5
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- carnitine palmitoyltransferase 1, gluconeogenesis, glucose homeostasis, antidiabetic drugs, insulin sensitivity, hepatic triglycerides, type 2 diabetes, db/db mice, high-fat diet, ketone bodies, insulin tolerance test, hyperinsulinemic-euglycemic clamp
- MeSH terms
- Analysis of Variance, Animals, Carnitine, Carnitine O-Palmitoyltransferase, Diabetes Mellitus, Type 2, Dietary Fats, Gluconeogenesis, Glucose, Heart, Homeostasis, Insulin Resistance, Liver, Male, Myocardium, Rats, Sprague-Dawley, Area Under Curve, Hepatocytes, PPAR alpha, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis. https://app.cochat.ai/papers/10.2337/db10-0346
- The paper
- Conti, R., Mannucci, E., Pessotto, P., Tassoni, E., Carminati, P., Giannessi, F., & Arduini, A. (2011). Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis. Diabetes. https://doi.org/10.2337/db10-0346
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.